Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
Subscribe To Our Newsletter & Stay Updated
